Patent Issued for Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies (USPTO 11999777).
In: Medical Letter on the CDC & FDA, 2024-06-25, S. 3980-3980
serialPeriodical
Zugriff:
Regeneron Pharmaceuticals Inc. has been issued a patent for methods of treating or preventing SARS-CoV-2 infections and COVID-19 using anti-SARS-CoV-2 spike glycoprotein antibodies. The patent provides information on the background of coronaviruses, the identification of SARS-CoV-2 as the cause of COVID-19, and the severity of the disease. The methods described in the patent involve administering therapeutic or prophylactic compositions containing antigen-binding molecules to improve clinical parameters or prevent infection. The patent includes specific amino acid sequences for the antigen-binding molecules and may be of interest to researchers studying COVID-19 therapeutics and immunology. [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies (USPTO 11999777).
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2024-06-25, S. 3980-3980 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Schlagwort: |
|
Sonstiges: |
|